IDO1 and melanoma: A previous phase III clinical trial in advanced melanoma examined the clinical benefit of combining an IDO1 inhibitor (epacadostat) with a PD‐1 inhibitor (pembrolizumab); the results indicated that patients failed to benefit significantly from the treatment.32